Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 27, 2009 Brian Orelli	When Will Someone Buy Natus Medical? This stock is sporting much lower multiples, waiting for its next big move, and doing everything it can to boost the bottom line.
The Motley Fool September 30, 2009 Brian Orelli	Bigger Size, Lower Returns History is not on Merck and Schering's side.
The Motley Fool January 25, 2006 Rick Casterline	Is BABY Born Again? Natus Medical's 200% growth may be just the beginning. Between its international and domestic efforts, the company is firing on all cylinders. Investors, take note.
The Motley Fool November 3, 2009 Rich Smith	Is BABY Back? Natus Medical beat earnings, but can it continue to top the S&P 500?
The Motley Fool April 3, 2009 Rich Smith	BABY Cries When She's Hungry Natus Medical is starved for sales.
The Motley Fool January 23, 2009 Robert Steyer	BAX to the Future After minding its own business, Baxter International starts thinking about acquisitions again.
The Motley Fool August 7, 2007 Rich Smith	Oops, BABY Doesn't Bounce Mr. Market drops Natus Medical. Is now the time to buy in?
The Motley Fool September 3, 2009 Brian Orelli	Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing.
The Motley Fool August 11, 2004 Rich Smith	Natus Medical's Prognosis Infant-care specialist Natus Medical promises a profit next quarter.
The Motley Fool October 19, 2005 Stephen D. Simpson	Abbott Still a Little Pale Perhaps drug and device pipelines, plus margin improvements, can put some color back into the diversified health-care company's stock.
The Motley Fool August 1, 2006 Rich Smith	Foolish Forecast: Natus' Time-Out Over? The infant health specialist missed analyst consensus earnings estimates last quarter. The stock fell 40% from its high to today's $12 and change. Tomorrow, shareholders will be looking for just that -- change -- when it reports its second-quarter earnings.
The Motley Fool March 16, 2007 Tim Hanson	Natus Medical vs. Under Armour: Natus Medical In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Natus Medical may be small, but it can bring the noise for investors.
The Motley Fool November 11, 2008 Brian Orelli	AOB Is A-OK Growing through acquisitions seems to be working.
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool September 30, 2009 Brian Orelli	Boston Scientific Pays Up And Johnson & Johnson reaps the rewards.
The Motley Fool April 15, 2009 Brian Orelli	Johnson & Johnson Still Withstands Recession While Johnson & Johnson is big, it has proven to be agile during the recession, and this quarter was no different.
The Motley Fool February 1, 2010 Brian Orelli	Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost.
The Motley Fool May 1, 2006 Rich Smith	Foolish Forecast: Natus Medical's Prognosis With a better than 130% rise in stock price over the last year, this young medical device maker is looking quite healthy. Just to be safe, though, let's take a look at its latest earnings report.
The Motley Fool January 22, 2009 Brian Orelli	Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool October 16, 2009 Robert Steyer	Baxter Beats Again -- the Streak Is Alive! The drug, device, and medical services giant beats Wall Street earnings estimates by a penny, but flat sales signal caution.
The Motley Fool October 17, 2006 Brian Lawler	See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note.
The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
The Motley Fool November 10, 2004 Rich Smith	Natus Delivers Infant care equipment maker proves true to its word. For the year to come, Natus expects revenues of from $41 million to $43 million to translate into diluted per-share profits of $0.26 to $0.28.
The Motley Fool February 24, 2011 Brian Orelli	Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool October 31, 2008 Brian Orelli	A Generic McMansion Mylan took an awfully big bite when it purchased Merck KGaA's generic-drug business last year, but so far it's proven that it can handle it.
The Motley Fool February 28, 2008 Brian Orelli	Mylan Almost Triples Revenue -- Big Deal Mylan's growth seems impressive last year, but that growth was all extrinsic, and it came at a cost.
The Motley Fool July 27, 2011	Natus Medical Earnings Preview Natus Medical will unveil its latest earnings on Thursday, July 28.
The Motley Fool February 26, 2004 Dave Marino-Nachison	Engineered Support's System Solid profit margins and successful acquisitions are helping the military contractor grow.
The Motley Fool July 30, 2007 Brian Orelli	Mega Mylan Is on Track Comparing year-over-year results for Mylan will continue to be complicated for the next year and a half or so. It's one merger down, one to go for the generic drug company. Investors, take note.
The Motley Fool January 30, 2007 Brian Lawler	Is Bigger Better for Abbott Labs? Abbott continues its transformation into a more focused pharmaceutical powerhouse. But shares of this pharmaceutical aren't exactly cheap.
The Motley Fool April 17, 2009 Robert Steyer	The Steady BAX Beat Baxter International's diverse medical offerings continue to produce prosperity.
The Motley Fool January 28, 2009 Brian Orelli	The Streak Is Over After 31 consecutive quarters of double-digit sales growth, medical device maker Stryker finally had an off quarter.
The Motley Fool November 2, 2009	Today's 5-Star Movers Today's list of top-moving stocks from the Motley Fool five-star stock list: Qiao Xing Mobile Communication Co... Natus Medical... Cresud, Inc...
InternetNews January 6, 2011	Microsoft Loses Two Acquisition Execs Microsoft bids farewell to two leaders of its mergers and acquisitions division, including the executive who was enmeshed in the company's effort to purchase Yahoo in 2008.
The Motley Fool April 30, 2009 Brian Orelli	A Great Generic Recovery After getting punished for taking on an acquisition, Mylan is doing pretty well.
The Motley Fool May 12, 2004 Phil Wohl	Mylan's Big Break? The maker of generic pimple cream wants to lead the pack. Can it?
The Motley Fool September 3, 2009 Matt Koppenheffer	Roundtable: Small Caps on the Buyout Radar Acquisition candidates are most interesting when they don't need a buyout to be a great investment.
The Motley Fool June 10, 2011 Matt Koppenheffer	5 Companies Ready to Make Acquisitions Could corporate deal-making help drive the market in the second half of the year?